| Literature DB >> 35079539 |
Izumi Yamaguchi1, Yasuhisa Kanematsu1, Kenji Shimada1, Kohei Nakajima1, Takeshi Miyamoto1, Shu Sogabe1, Eiji Shikata1, Manabu Ishihara1, Mai Azumi1, Ayato Kageyama1, Yasushi Takagi1.
Abstract
The gelatin-thrombin matrix, Floseal, is an excellent novel hemostatic agent that is used in various surgical fields. Thrombin is a serine protease, and the conversion of prothrombin to thrombin is an essential step in the coagulation cascade. However, thrombin can induce blood-brain barrier (BBB) disruption and vasogenic brain edema. This report describes two cases of gelatin-thrombin matrix-related cyst formation after cerebral hematoma evacuation. An 82-year-old man with a gelatin-thrombin matrix-related cyst was treated by cyst drainage and fenestration to the lateral ventricle. Histological evaluation of the cyst wall showed a gelatin-thrombin matrix reserve, marked infiltration of inflammatory cells, and foam cell accumulation. In addition, an 85-year-old woman with a gelatin-thrombin matrix-related cyst was treated with steroids and responded well. In both cases, the post-treatment course was uneventful. Cyst shrinkage and no recurrence were observed. The gelatin-thrombin matrix can cause cyst formation with brain edema. This is the first report demonstrating the cyst wall pathology and the steroid responsivity on cyst shrinkage. The mechanism of cyst formation is thought to be thrombin-induced BBB disruption. Excess gelatin-thrombin matrix should be carefully removed from the surgical beds, particularly those having a blinded space from the neurosurgical microscope.Entities:
Keywords: Floseal matrix; blood–brain barrier; cerebral hemorrhage; cysts; gelatin–thrombin hemostatic matrix
Year: 2021 PMID: 35079539 PMCID: PMC8769470 DOI: 10.2176/nmccrj.cr.2021-0130
Source DB: PubMed Journal: NMC Case Rep J ISSN: 2188-4226
Fig. 1Brain CT on day 1 (A) and day 7 (B) after admission. (C) Brain CT on postoperative day 1 showing hematoma disappearance and pseudoair hypoattenuation (*) estimated with lung windows (window widths of 1500). (D) Brain CT on postoperative day 5 indicating subfalcine herniation caused by the cyst in the hematoma cavity. CT: computed tomography.
Fig. 2(A–E) Brain MR imaging on postoperative day 5 demonstrating the cyst in the hematoma cavity. Diffusion-weighted image showing hyperintensity at the cyst wall (A). T1-weighted image showing isointensity (B). T2-weighted image showing hyperintensity (C). Cyst wall enhancement on axial (D) and coronal (E) MR images after gadolinium administration. (F) Intraoperative view indicating the whitish areolar tissue and fluid accumulation in the cyst. (G) Red-brown sterile fluid in the cyst. (H and I) Hematoxylin and eosin staining demonstrating eosinophilic acellular material and infiltration of inflammatory cells (H) and foam cell accumulation (I). Scale bar = 100 µm. MR: magnetic resonance.
Fig. 3Brain CT on day 1 after admission (A) and postoperative day 1 (B). (C) Brain CT on postoperative day 15 showing the cyst in the hematoma cavity. (D) Brain CT on postoperative day 25 indicating cyst shrinkage after steroid treatment. CT: computed tomography.
Fig. 4(A–E) Brain MR imaging on postoperative day 16 demonstrating the cyst in the hematoma cavity. Diffusion-weighted image showing hyperintensity on the cyst wall (A). T1-weighted image showing hyperintensity (B). T2-weighted image showing hyperintensity (C). Cyst wall enhancement on axial (D) and coronal (E) MR images after gadolinium administration. (F–J) Brain MR imaging on postoperative day 33 demonstrating cyst shrinkage after steroid treatment. Diffusion-weighted image (F). T1-weighted image (G). T2-weighted image (H). Axial (I) and coronal (J) MR images after gadolinium administration. MR: magnetic resonance.